Company intelligence / Profile preview

Huarui Pharmaceutical

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Sino-American Huarui Pharmaceutical (SAPP) is a leading pharmaceutical joint venture in China, primarily owned by Fresenius Kabi. Established in 1982 as the first pharmaceutical joint venture in the country, the company specializes in clinical nutrition and intravenous therapy. Its product portfolio includes parenteral and enteral nutrition solutions, such as amino acids, fat emulsions, and vitamins, as well as various injectable drugs. SAPP operates large-scale manufacturing facilities in Wuxi, China, and serves as a critical hub for Fresenius Kabi's operations in the Asia-Pacific region.

Therapeutic areas: EndocrinologyOtherMetabolic Disorders
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Drug pipeline

1 asset

Anrekefen (flurbiprofen axetil)

Partnerships

Fresenius KabiChina National Pharmaceutical Group (Sinopharm)

Beyond the preview

Go deeper on Huarui Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huarui Pharmaceutical.